This site is intended for health professionals only!
AstraZeneca today announced new health economics data from a substudy of the PLATO trial showed that treating a broad spectrum of acute coronary syndrome (ACS) patients with BRILIQUE™ (ticagrelor) was more cost-effective than treatment with generic clopidogrel.
The study demonstrated that ticagrelor provided a cost-effective gain in quality-adjusted life year (QALY) compared to generic clopidogrel based on the approved ticagrelor label in the EU.
Specifically, ACS patients treated with ticagrelor and aspirin, compared with generic clopidogrel plus aspirin for one year on average were projected to gain an additional 0.13 QALYs at a cost range of €2,350–€5,700 per QALY.
The PLATO trial (A Study of PLATelet Inhibition and Patient Outcomes) was the pivotal phase III study that formed the basis of the EU label.
Cost per QALY is an important measure used by national governments and their reimbursement agencies to assess cost effectiveness of medical treatments.
While no universal threshold for cost effectiveness exists, generally, a cost per QALY in the range of €25,000 to €38,000 is considered cost effective.
“The PLATO health economics substudy accounts for both the clinical effect observed in PLATO as well as cost considerations for treating ACS patients with ticagrelor versus clopidogrel,” said Dr Lars Wallentin, Director and Professor of Cardiology, Uppsala Clinical Research Centre and University Hospital, Sweden.
“What is particularly impressive about this substudy is that even at a higher price, ticagrelor was a cost effective treatment for ACS patients compared to generic clopidogrel.”
The price of generic clopidogrel €0.17 per day was compared with the price range of BRILIQUE of €2.25 to €3.50 per day and applied in the analysis to form the price component of the health economics substudy.
Using individual patient data from PLATO and event rates, health care costs based on Swedish base-case analysis and QALYs were estimated for the first year.
The analysis showed that the overall cost impact of using ticagrelor instead of clopidogrel was cost effective.
The analysis is now published in the May/June issue of the International Society for Pharmacoeconomics and Outcomes Research’s Value in Health and will be presented at the organisation’s international annual meeting on 23 May.
AstraZeneca also announced today that ticagrelor has been accepted for reimbursement by the Scottish Medicines Consortium (SMC) for patients in Scotland. The Ministry of Health and Prevention in Denmark also recently approved ticagrelor as the first branded oral antiplatelet therapy to achieve national reimbursement for a broad ACS population.
Health technology assessments ongoing in the remainder of the UK and in Germany are expected later this year by NICE and IQWiG, respectively, however healthcare professionals are able to prescribe ticagrelor in accordance with local guidance. Markets where a price has been approved but the reimbursement process is ongoing include Finland, Norway, Portugal and Austria.
“These new data help further demonstrate the compelling value proposition ticagrelor offers versus a widely used generic. We also welcome the positive decision in Scotland and Denmark to reimburse ticagrelor and believe it will become an attractive option for physicians seeking another antiplatelet treatment to reduce their ACS patients’ risk of heart attack and cardiovascular death,” said Tony Zook, Executive Vice President of AstraZeneca’s Global Commercial Organisation.
“Further reimbursement processes are underway according to local rules and regulations and timings will differ from market to market. We will continue to work with the appropriate health organisations, formulary and protocol review boards, and clinicians to ensure patients have access to this important medicine as soon as possible.”